Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2017-10-17 |
Gemini therapeutics (USA - MA) |
$42.5 Million |
series A financing round |
Atlas Venture (USA-MA) Lightstone Ventures (USA-CA) OrbiMed (USA-NY) |
Rare diseases - Genetic diseases- Ophthalmological diseases |
Series A financing round |
2017-10-13 |
InflaRX (Germany) |
$ 55 million |
series D financing round |
Bain Capital Life Sciences (USA) Cormorant Asset Management (USA) RA Capital Management (USA) undisclosed investment funds managed by a leading US investment management firm |
Inflammatory diseases |
Series D financing round |
2017-10-09 |
Faron Pharmaceuticals (Finland) |
£10.0 million |
private placement |
|
Cardiovascular diseases |
Private placement |
2017-10-02 |
KSQ Therapeutics (USA - MA) |
$76 million |
financing round |
Flagship Pioneering (USA - MA) Polaris Partners (USA - MA) ARCH Venture Partners (USA - IL) Alexandria Equities (USA - CA) |
Cancer - Oncology - Immunological diseases |
Financing round |
2017-09-26 |
Juno Therapeutics (USA - WA) |
$318.7 million |
private placement |
|
Cancer - Oncology |
Private placement |
2017-09-25 |
Deep Genomics (Canada) |
$13 million |
financing round |
Khosla Ventures (USA - CA) True Ventures (USA - CA) |
Technology - Services |
Financing round |
2017-09-25 |
eTheRNA immunotherapies (Belgium) |
€1 million |
grant |
Flanders Innovation & Entrepreneurship (VLAIO) (Belgium) |
Cancer - Oncology |
Grant |
2017-09-25 |
Iovance Biotherapeutics (USA - CA) |
$57.5 million. |
private placement |
|
Cancer - Oncology |
Private placement |
2017-09-22 |
DaVolterra (France) |
€ 20 million |
loan |
European Investment Bank (EIB) |
Infectious diseases |
Loan |
2017-09-22 |
Krystal Biotech (USA - PA) |
$45,54 million |
IPO |
|
Dermatological diseases |
IPO |
2017-09-19 |
Epizyme (USA - MA) |
$151.3 million |
private placement |
|
Cancer - Oncology |
Private placement |
2017-09-18 |
Evotec (Germany) |
up to € 75 million |
loan |
European Investment Bank (EIB) |
Technology - Services |
Loan |
2017-09-18 |
Soligenix (USA - NJ) |
$1.5 million |
grant |
National Cancer Institute (NCI) (USA) |
Cancer - Oncology |
Grant |
2017-09-13 |
Genenta Science (Italy) |
$8,4 Million (€7 Million) |
series B financing round |
Italian, British, and Swiss private investors, family offices, business angels, Banca Esperia (Italy) Mediolanum (Italy), board members |
Cancer - Oncology |
Series B financing round |
2017-09-11 |
IGEM Therapeutics (UK) |
£2 million |
series A financing round |
Epidarex Capital (UK) |
Cancer - Oncology |
Series A financing round |
2017-09-11 |
Amphivena Therapeutics (USA - CA) |
|
series B financing round |
Tekla Capital Management (USA - MA) |
Cancer - Oncology - Rare diseases |
Series B financing round |
2017-08-28 |
Apeiron Biologics (Austria) |
€ 25 million |
grant |
European Investment Bank (EIB) |
Cancer - Oncology |
Grant |
2017-08-15 |
Omeros (USA - Wn) |
|
private placement |
|
|
Private placement |
2017-08-15 |
Dynavax (USA - CA) |
$80.8 million |
private placement |
|
Infectious diseases |
Private placement |
2017-08-09 |
Spark Therapeutics (USA - PA) |
$380.4 million |
private placement |
|
|
Private placement |